All In MedTech

Device Trial Radar · NCT06978907

Evaluation of the Efficacy and Safety of Lactobacillus Crispatus M247 (Crispact®) With Vaginal Laser Therapy in Menopausal Women With Atrophic Vulvovaginitis (VVA)

Evaluation of the Efficacy and Safety of Lactobacillus Crispatus M247 (Crispact®) in Combination With Vaginal Laser Therapy for Improving Vaginal Microbiota Composition and Symptomatology in Menopausal Women With Atrophic Vulvovaginitis: A Prospective, Multicenter, Randomized, Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Jul 1, 2025

Primary completion

Nov 27, 2025

Study completion Dec 9, 2025

Sponsor

Lead sponsor
Liaquat University of Medical & Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Università degli Studi dell'Insubria
First posted
May 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, controlled, prospective, multicenter study aims to evaluate the efficacy and safety of Lactobacillus crispatus M247 in combination with vaginal laser therapy for improving vaginal microbiota composition and reducing genitourinary symptoms in menopausal women with atrophic vulvovaginitis (VVA). Participants will be randomized into two groups: one receiving laser therapy alone and the other receiving laser therapy combined with daily administration of the probiotic Lactobacillus crispatus M247 (Crispact®). Primary outcomes include changes in genitourinary symptoms assessed using a validated vulvovaginal symptom questionnaire and evaluation of safety. Secondary outcomes include changes in vaginal microbiota composition.

Conditions

  • Atrophic Vulvovaginitis

Interventions

  • Monnalisa Touch® Laser TherapyDevice

    Monnalisa Touch® laser therapy is a non-ablative fractional CO2 laser applied to the vaginal mucosa to promote tissue regeneration and maintain vaginal health. Participants in this group will receive three sessions of laser therapy, one session every 30 days.

  • Monnalisa Touch® Laser Therapy + Lactobacillus crispatus M247 (Crispact®)Combination product

    Participants in this group will receive three sessions of Monnalisa Touch® laser therapy, one session every 30 days, along with daily administration of Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU, taken orally for three months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Genitourinary SymptomsTime frame: Baseline (T0) to Month 3 (M3).
  2. Safety AssessmentTime frame: Baseline (T0) to Month 3 (M3).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Villa Margherita Clinic

    Roma, Italy

  • Hospital State of Republic of San Marino

    San Mariano, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.